Last reviewed · How we verify
Letrozole Oral Product
Aromatase inhibitor
Aromatase inhibitor Used for Breast cancer.
At a glance
| Generic name | Letrozole Oral Product |
|---|---|
| Sponsor | Gynaecologisch Oncologisch Centrum Zuid |
| Drug class | Aromatase inhibitor |
| Target | Aromatase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Letrozole works by inhibiting the enzyme aromatase, which is involved in the biosynthesis of estrogen. By blocking this enzyme, letrozole reduces estrogen levels in the body, which can help slow the growth of hormone receptor-positive breast cancer cells.
Approved indications
- Breast cancer
Common side effects
- Hot flashes
- Vaginal dryness
- Headache
Key clinical trials
- ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors (PHASE1, PHASE2)
- Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (PHASE2)
- Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer (PHASE2)
- DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment (PHASE2)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer (PHASE2)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
- Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Letrozole Oral Product CI brief — competitive landscape report
- Letrozole Oral Product updates RSS · CI watch RSS
- Gynaecologisch Oncologisch Centrum Zuid portfolio CI